Progyny, Inc. (NASDAQ:PGNY) Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. boosted its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 9.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,659 shares of the company’s stock after acquiring an additional 1,755 shares during the quarter. Pacer Advisors Inc.’s holdings in Progyny were worth $562,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Nordea Investment Management AB lifted its stake in shares of Progyny by 122.2% in the 1st quarter. Nordea Investment Management AB now owns 126,446 shares of the company’s stock valued at $4,891,000 after purchasing an additional 69,552 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Progyny by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 756,228 shares of the company’s stock worth $21,636,000 after acquiring an additional 22,012 shares in the last quarter. Kestrel Investment Management Corp acquired a new stake in shares of Progyny during the 2nd quarter valued at about $5,005,000. Hsbc Holdings PLC increased its stake in shares of Progyny by 703.9% in the 2nd quarter. Hsbc Holdings PLC now owns 46,475 shares of the company’s stock valued at $1,328,000 after purchasing an additional 40,694 shares in the last quarter. Finally, Jennison Associates LLC raised its holdings in Progyny by 2.7% in the 1st quarter. Jennison Associates LLC now owns 2,596,422 shares of the company’s stock worth $99,054,000 after purchasing an additional 67,632 shares during the period. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Trading Up 0.5 %

PGNY stock opened at $16.80 on Friday. The firm has a 50-day moving average of $22.88 and a two-hundred day moving average of $27.97. Progyny, Inc. has a 12 month low of $13.93 and a 12 month high of $42.08. The company has a market cap of $1.52 billion, a price-to-earnings ratio of 27.54, a PEG ratio of 1.62 and a beta of 1.45.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.17 EPS for the quarter, hitting analysts’ consensus estimates of $0.17. The firm had revenue of $304.09 million for the quarter, compared to the consensus estimate of $305.32 million. Progyny had a return on equity of 11.97% and a net margin of 5.54%. The firm’s revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.15 earnings per share. As a group, equities analysts forecast that Progyny, Inc. will post 0.64 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PGNY. Canaccord Genuity Group cut Progyny from a “buy” rating to a “hold” rating and cut their price objective for the company from $37.00 to $24.00 in a research report on Wednesday, August 7th. Cantor Fitzgerald reduced their price objective on shares of Progyny from $37.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, September 19th. Canaccord Genuity Group decreased their price objective on shares of Progyny from $24.00 to $18.00 and set a “hold” rating on the stock in a report on Friday, September 20th. Leerink Partnrs downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, BTIG Research lowered shares of Progyny from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Progyny presently has a consensus rating of “Hold” and a consensus price target of $27.73.

Insider Activity

In related news, President Michael E. Sturmer sold 9,030 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $30.00, for a total transaction of $270,900.00. Following the completion of the sale, the president now directly owns 362,583 shares in the company, valued at $10,877,490. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 12.30% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.